University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; and.
Buffalo General Medical Center, Buffalo, NY.
J Cardiovasc Pharmacol. 2023 May 1;81(5):355-360. doi: 10.1097/FJC.0000000000001412.
Beta-blockers (BBs) have proven to improve morbidity and mortality in patients after an ST elevation myocardial infarction (STEMI). Guidelines suggest initiating a BB within 24 hours, except in those with risk factors for developing cardiogenic shock, although published literature is conflicting regarding the true association of these risk factors with shock. This retrospective cohort study aimed to assess whether the presence of defined risk factors was associated with cardiogenic shock after early BB administration in patients with a STEMI and percutaneous coronary intervention. The primary outcome determined the rate of cardiogenic shock development and secondarily determined any characteristics associated with cardiogenic shock in patients who received beta blockers. The population included 299 patients and cardiogenic shock occurred in 8 patients (2.7%). There were no median (interquartile range) differences in age [63 years (60-71) versus 62 years (52-71); P = 0.4965], systolic blood pressure [110 mm Hg (105-115) versus 109 mm Hg (103-114); P = 0.6027], or heart rate [90 (78-104) versus 76 (64-90); P = 0.0697] before BB administration in patients who developed shock versus those who did not, respectively. Hours to BB administration from arrival [15.6 (6.0-54.8) versus 21.9 (10.6-42; P = 0.6968] and the number (%) with anterior infarction [3 (37.5%) versus 107 (36.8%); P = 1.000] were similar between groups. There was a statistically significant higher median (interquartile range) peak troponin [140 ng/mL (54-304) versus 49 ng/mL (16-132); P = 0.0354] in patients who developed shock. Early initiation of a BB in patients with STEMI and percutaneous coronary intervention with risk factors for cardiogenic shock does not seem to be associated with shock in most patients.
β受体阻滞剂(BBs)已被证明可改善 ST 段抬高型心肌梗死(STEMI)患者的发病率和死亡率。指南建议在 24 小时内开始使用 BB,但对于有发生心源性休克风险的患者除外,尽管已发表的文献对于这些风险因素与休克之间的真正关联存在争议。本回顾性队列研究旨在评估在接受经皮冠状动脉介入治疗的 STEMI 患者中,早期使用 BB 后,是否存在定义的风险因素与心源性休克相关。主要结局确定心源性休克的发展率,其次确定接受β受体阻滞剂治疗的患者中与心源性休克相关的任何特征。该人群包括 299 例患者,有 8 例(2.7%)发生心源性休克。心源性休克患者与未发生休克患者相比,BB 给药前的年龄[中位数(四分位间距):63 岁(60-71)与 62 岁(52-71);P=0.4965]、收缩压[中位数(四分位间距):110 mmHg(105-115)与 109 mmHg(103-114);P=0.6027]和心率[中位数(四分位间距):90(78-104)与 76(64-90);P=0.0697]差异无统计学意义。从到达到 BB 给药的时间[中位数(四分位间距):15.6(6.0-54.8)与 21.9(10.6-42);P=0.6968]和前壁梗死的患者比例[3(37.5%)与 107(36.8%);P=1.000]在两组之间相似。发生休克的患者的肌钙蛋白峰值[中位数(四分位间距):140 ng/mL(54-304)与 49 ng/mL(16-132);P=0.0354]显著更高。在大多数患者中,对有发生心源性休克风险的 STEMI 患者和接受经皮冠状动脉介入治疗的患者早期使用 BB 似乎与休克无关。